36 results on '"Pitale, S."'
Search Results
2. Development and characterization of polycrystalline transparent CsI plate for X-ray radiography applications
- Author
-
Sen, Shashwati, Sarkar, P.S., Patra, G.D., Singh, S.G., Ghosh, M., Pitale, S., Patil, A.N., and Pal, Manoj K.
- Published
- 2021
- Full Text
- View/download PDF
3. Tunable blue-green emission from ZnS(Ag) nanostructures grown by hydrothermal synthesis
- Author
-
Sharma, Manjula, Sen, Shashwati, Gupta, Jagannath, Ghosh, M., Pitale, S., Gupta, Vinay, and Gadkari, S. C.
- Published
- 2018
- Full Text
- View/download PDF
4. Multiplex PCR in diagnosis and characterization of bovine viral diarrhoea virus isolates from India
- Author
-
Mishra, N., Pitale, S. S., Jain, P., and Pradhan, H. K.
- Published
- 2005
5. Spectral and surface investigations of Mn2+ doped SrZnO2 nanocrystalline phosphors
- Author
-
Bedyal, A. K., Kumar, Vinay, Sharma, Vishal, Pitale, S. S., Coetsee, E., Duvenhage, M. M., Ntwaeaborwa, O. M., and Swart, H. C.
- Published
- 2013
- Full Text
- View/download PDF
6. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes
- Author
-
Yang, S. J., Min, K. W., Gupta, S. K., Park, J. Y., Shivane, V. K., Pitale, S. U., Agarwal, P. K., Sosale, A., Gandhi, P., Dharmalingam, M., Mohan, V., Mahesh, U., Kim, D. M., Kim, Y. S., Kim, J. A., Kim, P. K., and Baik, S. H.
- Published
- 2013
- Full Text
- View/download PDF
7. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial
- Author
-
Pattzi, H. M. R., Pitale, S., Alpizar, M., Bennett, C., OʼFarrell, A. M., Li, J., Cherrington, J. M., and Guler, H.-P.
- Published
- 2010
- Full Text
- View/download PDF
8. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- Author
-
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, Josse RG, Califf RM, Goldstein BJ, Shapiro DR, Silverman R, Bethel A, Green J, Hayden S, Hannan K, Quintero K, Rorick T, Berdan L, Leloudis D, Califf S, Wilson M, McFarron D, Trollinger K, Pesarchick J, Eskenazi L, Campbell C, Townes O, Tolsma D, Keenan J, Milton J, Athwal R, Darbyshire J, Doran Z, Kennedy I, Gregory V, Lokhnygina Y, Prather K, Wolfley A, Usman M, Tajjar A, Gray R, Pfeffer MA, Gerstein HC, Groop L, McMurray JJ, Pocock SJ, Clayton T, Sinay I, Brieger D, Stranks S, Scheen A, Lopes R, Tankova T, Hramiak I, Grado CR, Wenying Y, Ge J, Aschner P, Skrha J, Ambos A, Strandberg T, Travert F, Hanefeld M, Riefflin A, Chan JC, Ofner P, Reddy NK, Christopher J, Mathur A, Arambam P, Mittal S, Manchanda M, Wainstein J, Ambrosio G, Pirags V, Jakuboniene N, Mohamed M, Scott R, White H, Cornel J, Halvorsen S, Tykarski A, Veresiu IA, Dreval AV, Misinkova I, Tai E, Krahulec B, Distiller L, Park Y, Rovira A, Alversson M, Chuang LM, Delibasi T, Adler A, Rodbard HW, Marre M, Goff D, Chacra A, DeVore A, Beaven A, Shah B, Hirsch B, Batch B, Bushnell C, Patel C, Melloni C, Henshaw C, Kong D, Bernecki G, Tillman H, Kang HJ, Hawes J, Strickler J, Piccini J, Wilder J, Alexander K, Mahaffey K, Patel K, Hyland K, Newby K, Jackson L, Cooper L, Armaganijan L, Szczeh L, Koshizaka M, Roe M, Morse M, Guimaraes P, Hess P, Tricoci P, Mehta R, Mathews R, Kociol R, Harrison R, Mentz R, Pokorney S, Leblanc T, Lazzarini V, Eapen Z, Truffa A, Fosbol E, Brito F, Katz M, Bahit M, Santos M, Barros P, Bernardez S, Alvarisqueta AF, Arias P, Cagide AL, Calella PR, Cantero MC, Canella JP, Cipullo MA, de Loredo L, Gelersztein ES, Gorban de Lapertosa SB, Klyver MI, Maffei LE, Maldonado N, Oviedo AI, Piskorz DL, Ridruejo MC, Saavedra SS, Sessa HA, Sinay IR, Sposetti GD, Ulla MR, Vico ML, Waitman JN, Binnekamp M, Carroll P, Cheung W, Colman P, Davis T, De Looze F, dEmden M, Fulcher G, Gerstman M, Hamilton A, Lehman S, Moses R, Proietto J, Roberts A, Shaw J, Simpson R, Sinha A, Tan Y, Topliss D, Vora P, Waites J, Crenier L, Descamps O, Keymeulen B, Mathieu C, Nobels F, Van den Bruel A, Van Gaal L, Borges JL, Costa e Forti A, Eliaschewitz FG, Felício JS, Griz LH, Hissa MN, Leite S, Panarotto D, Pimentel Filho P, Rassi N, Saraiva JK, Sgarbi JA, Silva RP, Tambascia M, Weber Silva DM, Bobeva R, Bostandzhieva R, Cinlikov I, Georgieva M, Iliev D, Ilieva E, Kovacheva S, Liubenova L, Nikitov Z, SHeinikova G, Slavcheva A, Spasova V, Temelkova-Kurktschiev T, Velichka D, Yakov A, Carpentier A, Chiasson JL, Constance C, Dumas R, Filteau P, Garceau C, Huynh T, Kaiser S, Kornder J, Leiter L, Mereu L, Miller D, Pandey S, Punthakee Z, Rabasa-Lhoret R, Robitaille Y, Saunders K, Sigal R, Sigalas J, Vizel S, Weisnagel S, Woo V, Yale JF, Yared K, Zinman B, Bunster Balocchi LB, Escobar Cerda EE, Garces Flores EE, Lanas Zanetti FT, Larrazabal Miranda Adel P, Morales Alvarado JM, Olivares Cañon CM, Potthoff Cárdenas SH, Raffo Grado CA, Rodriguez Venegas ME, Saavedra Gajardo VA, Westerberg Maldonado BH, Chen LL, Dong J, Guo X, Li QM, Shi B, Tang XL, Yang T, Yang WY, Zheng SX, Aschner Montoya P, Botero Lopez R, Coronel Arroyo JA, Cure CA, Gómez Medina AM, Molina DI, Perez Amador GA, Reyes Rincon A, Urina Triana MA, Valenzuela Rincon A, Vélez Pelaez S, Yupanqui Lozno H, Brabec T, Brychta T, Hasalova Zapletalova J, Havelkova J, Hejnicova K, Hola O, Hornackova M, Hrdina T, Kafkova D, Kellnerova I, Krystl T, Kutejova V, Mikulkova I, Nevrla J, Pantlikova C, Petr M, Racicka E, Sarbochova R, Smolenakova K, Turcinek R, Urbancova K, Vejvodova J, Vondrakova M, Zachoval R, Alt I, Kaasik Ü, Kiiroja K, Lanno R, Märtsin K, Past M, Vides H, Viitas L, Kantola I, Nieminen S, Perhonen M, Strand J, Valle T, Clergeot A, Couffinhal T, Courreges JP, Gouet D, Moulin P, Ziegler O, Badenhoop K, Behnke T, Bender G, Braun M, Dshabrailov J, Hamann A, Himpel-Boenninghoff A, Kamke W, Kasperk C, Luedemann J, Mayr P, Merkel M, Oerter EM, Ohlow MA, Ott P, Overhoff U, Paschen B, Remppis R, Rose L, Schumm-Draeger PM, Segiet T, Strotmann HJ, Stuchlik G, Stürmer W, Thinesse-Mallwitz M, Tytko A, Wendisch U, Wurziger J, Ho AY, Kam G, Kong AP, Lam YY, Lau EY, Lee S, Siu SC, Tomlinson B, Tsang CC, Yeung VT, Dezső E, Dudás M, Földesi I, Fülöp T, Késmárki N, Koranyi L, Nagy K, Oroszlán T, Pécsvárady Z, Ples Z, Taller A, Agarwal P, Ambulkar S, Aravind S, Balaji V, Kalra S, Kesavadev J, Kudalkar H, Kumar A, Misra A, Mithal A, Mohan V, Pitale S, Ramu M, Reddy N, Shah S, Shamanna P, Sharda A, Sharma A, Shunmugavelu M, Srikanta S, Suryaprakash G, Abramov G, Adawi F, Bashkin A, Darawsha M, Fuchs S, Harman-Boehm I, Hayek T, Jaffe A, Knobler H, Minuchin O, Mosseri M, Shechter M, Shimon I, Stern N, Tsur A, Vishlitzky V, Alfonsi F, Cavalot F, Del Vecchio L, Frisinghelli A, Gambardella S, Lauro D, Lembo G, Leotta S, Mondillo S, Novo S, Pedrinelli R, Piatti P, Salvioni A, Tritto I, Zavaroni DZ, Ahn KJ, Choi KM, Chung C, Han SJ, Kim DM, Kim IJ, Kim MH, Lee IK, Nam M, Park IeB, Park KS, Park TS, Rhee EJ, Yoo SJ, Andersone I, Balode A, Eglite R, Gersamija A, Kakurina N, Jegere B, Leitane I, Pastare S, Stalte V, Teterovska D, Baltramonaitiene K, Barsiene L, Ceponis J, Lasiene J, Levinger A, Sirutaviciene A, Sulskiene M, Urbanaviciene L, Valius L, Varanauskiene E, Velickiene D, Mahendran KA, Abu Hassan MR, Aziz NA, Hussein Z, Ismail IS, Kamaruddin NA, Nordin Z, Nayar SK, Ramanathan GR, Sothiratnam R, Beijerbacht H, Breedveld R, Cornel JH, Den Hartog F, Hermans W, Kietselaer B, Kooy A, Lenderink T, Nierop P, Remmen J, Rojas Lingan G, Ronner E, Van der Heijden R, Van Hessen M, van Kempen W, Voors-Pette C, Westendorp I, Baker J, Benatar J, Cutfield R, Krebs J, Leikis R, Lunt H, Manning P, Williams M, Birkeland K, Claudi T, Istad H, Karlsson T, Ossum Gronert J, Arciszewska M, Artemiuk E, Blach E, Blicharski T, Cypryk K, Dabrowska M, Górny G, Górska M, Jakubowska I, Jazwinska-Tarnawska E, Karczmarczyk A, Kitowska-Koterla J, Koltowski L, Krzyzagorska E, Pasternak D, Pentela-Nowicka J, Piesiewicz W, Przekwas-Jaruchowska M, Rajzer M, Salamon-Ferenc A, Sawicki A, Skowron T, Śmiałowski A, Albota A, Alexandru C, Crisan C, Dumitrescu A, Ferariu IE, Lupusoru DA, Munteanu M, Negru D, Nicolau A, Pintiliei E, Popescu A, Serban G, Voitec M, Babenko A, Barbarash O, Bondar I, Chizhov P, Demin A, Dora S, Dreval A, Ershova O, Gratsiansky N, Ketova G, Kotelnikov M, Levashov S, Morugova T, Mustafina S, Pekarskiy S, Raskina T, Rechkova E, Samoylova Y, Sazonova O, Sherenkov A, Shilkina N, Stetsyuk O, Tretyakova T, Turova E, Valeeva F, Zadionchenko V, Dalan R, Tan RS, Tay L, Buganova I, Fabry J, Jan C, Toserova E, Zak R, Zimanova J, Badat A, Bester F, Burgess L, De Jong D, Ellis G, Fouche L, Govender P, Govind U, Naidoo V, Nieuwoudt G, Nortje H, Rheeder P, Robertson L, Siddique N, Stapelberg AM, Trinder Y, Van Der Merwe A, Van Zyl L, Viljoen M, Wilhase A, Botella M, Civeira Murillo F, de Teresa L, Del Cañizo FJ, Extremera BG, Gimeno EJ, Martin-Hidalgo A, Morales C, Nubiola A, Tinahones Madueño F, Tranche S, Trescolí Serrano C, Alvarsson M, Eizyk E, Gillblad A, Johansson P, Löndahl M, Ohlsson-Önerud Å, Rautio A, Sundström U, Torstensson I, Chen JF, Chou CW, Ho LT, Hsieh IC, Huang BH, Huang CL, Huang CN, Lai WT, Lo PH, Pei D, Sheu WH, Wang SY, Araz M, Bakiner O, Comlekci A, Guler S, Sahin I, Sarac F, Tarkun I, Ukinc K, Yilmaz M, Abdulhakim E, Abraham P, Adamson K, Blagden M, Bundy C, Daly M, Davies M, Deshpande M, Gillings S, Harvey P, Horvathova V, Hristova D, Jaap A, Johnson A, Jones H, Kerrane J, Kilvert A, Ko T, Kumar J, Lindsay R, Litchfield J, McCrimmon R, McKnight J, Millward B, Oyesile B, Purewal T, Ravikumar C, Robinson A, Sathyapalan T, Simpson H, Thomas H, Turner W, Weaver J, Wilding J, Wiles P, Adkins K, Akpunonu B, Albu J, Anagnostis G, Anastasi L, Argoud G, Aroda V, Azizad M, Banerji MA, Bartkowiak A Jr, Bays H, Behn P, Bergenstal R, Bhargava A, Bias D, Bolster E, Buchanan P, Busch R, Chadha C, Chang M, Cheng C, Cohen A, Cohen J, Cole B, Connery L, Cooperman M, Cushman W, DAgostino R, Dayamani P, De Lemos J, De Meireles M, Dean J, DeHart D, Detweiler R, Donovan D, Dugano-Daphnis P, Dulin M, Dunn F, Eaton C, Erickson B, Estevez R, Feinglos M, Fonseca V, Force R, Forker A, Fox D, Gabriel J, Garcia R, Garvey T, Gaudiani L, Getaneh A, Goldberg A, Goldman S, Hairston K, Harris R, Haught W, Hidalgo H Jr, Higgins A, Houchin V, Ison R, Jacobs G, Jaffrani N, Jafry B, Kapsner P, Kaye W, Labroo A, Levinson L, Lewis S, Lillestol M, Luttrell L, Madu I, McNeill R, Merrick B, Metzger F, Nadar V, Nagelberg S, Nash S, Oparil S, Osei K, Papademetriou V, Patel N, Pedley C, Prentiss A, Radbill M, Raisinghani A, Rassouli N, Reddy R, Rees P, Rendell M, Robbins D, Rodbard H, Rohlf J, Roseman H, Rudolph L, Sadler L, Schnall A, Schramm R, Schubart U, Seneviratne T, Shanik M, Snyder H, Sorli C, Stich M, Sweeney ME, Tsao J, Ukwade P, Viswanath D, Vo A, Vogel C, Voyce S, Weintraub H, White J, Wood M, Wu P, Wysham C, Zimmerman R, Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, and Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, Holman RR, Peterson ED, Holman RR, Peterson ED, Armstrong PW, Buse JB, Josse RG, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Engel SS, Califf RM, Goldstein BJ, Shapiro DR, Silverman R, Bethel A, Green J, Hayden S, Hannan K, Quintero K, Rorick T, Berdan L, Leloudis D, Califf S, Wilson M, McFarron D, Trollinger K, Pesarchick J, Eskenazi L, Campbell C, Townes O, Tolsma D, Keenan J, Milton J, Athwal R, Darbyshire J, Doran Z, Kennedy I, Gregory V, Garg J, Lokhnygina Y, Prather K, Wolfley A, Usman M, Tajjar A, Gray R, Pfeffer MA, Gerstein HC, Groop L, McMurray JJ, Pocock SJ, Clayton T, Sinay I, Brieger D, Stranks S, Scheen A, Lopes R, Tankova T, Hramiak I, Grado CR, Wenying Y, Ge J, Aschner P, Skrha J, Ambos A, Strandberg T, Travert F, Hanefeld M, Riefflin A, Chan JC, Ofner P, Reddy NK, Christopher J, Mathur A, Arambam P, Mittal S, Manchanda M, Wainstein J, Ambrosio G, Pirags V, Jakuboniene N, Mohamed M, Scott R, White H, Cornel J, Halvorsen S, Tykarski A, Veresiu IA, Dreval AV, Misinkova I, Tai E, Krahulec B, Distiller L, Park Y, Rovira A, Alversson M, Chuang LM, Delibasi T, Adler A, Rodbard HW, Marre M, Goff D, Chacra A, DeVore A, Beaven A, Shah B, Hirsch B, Batch B, Bushnell C, Patel C, Melloni C, Henshaw C, Kong D, McFarron D, Bernecki G, Tillman H, Kang HJ, Green J, Hawes J, Strickler J, Piccini J, Wilder J, Alexander K, Mahaffey K, Patel K, Hyland K, Newby K, Jackson L, Cooper L, Armaganijan L, Szczeh L, Koshizaka M, Roe M, Morse M, Guimaraes P, Hess P, Tricoci P, Mehta R, Lopes R, Mathews R, Kociol R, Harrison R, Mentz R, Pokorney S, Leblanc T, Lazzarini V, Eapen Z, Truffa A, Fosbol E, Brito F, Katz M, Bahit M, Santos M, Barros P, Bernardez S, Alvarisqueta AF, Arias P, Cagide AL, Calella PR, Cantero MC, Canella JP, Cipullo MA, de Loredo L, Gelersztein ES, Gorban de Lapertosa SB, Klyver MI, Maffei LE, Maldonado N, Oviedo AI, Piskorz DL, Ridruejo MC, Saavedra SS, Sessa HA, Sinay IR, Sposetti GD, Ulla MR, Vico ML, Waitman JN, Binnekamp M, Carroll P, Cheung W, Colman P, Davis T, De Looze F, dEmden M, Fulcher G, Gerstman M, Hamilton A, Lehman S, Moses R, Proietto J, Roberts A, Shaw J, Simpson R, Sinha A, Stranks S, Tan Y, Topliss D, Vora P, Waites J, Crenier L, Descamps O, Keymeulen B, Mathieu C, Nobels F, Scheen A, Van den Bruel A, Van Gaal L, Borges JL, Costa e Forti A, Eliaschewitz FG, Felício JS, Griz LH, Hissa MN, Leite S, Panarotto D, Pimentel Filho P, Rassi N, Saraiva JK, Sgarbi JA, Silva RP, Tambascia M, Weber Silva DM, Bobeva R, Bostandzhieva R, Cinlikov I, Georgieva M, Iliev D, Ilieva E, Kovacheva S, Liubenova L, Nikitov Z, SHeinikova G, Slavcheva A, Spasova V, Tankova T, Temelkova-Kurktschiev T, Velichka D, Yakov A, Carpentier A, Chiasson JL, Constance C, Dumas R, Filteau P, Garceau C, Hramiak I, Huynh T, Kaiser S, Kornder J, Leiter L, Mereu L, Miller D, Pandey S, Punthakee Z, Rabasa-Lhoret R, Robitaille Y, Saunders K, Sigal R, Sigalas J, Vizel S, Weisnagel S, Woo V, Yale JF, Yared K, Zinman B, Bunster Balocchi LB, Escobar Cerda EE, Garces Flores EE, Lanas Zanetti FT, Larrazabal Miranda Adel P, Morales Alvarado JM, Olivares Cañon CM, Potthoff Cárdenas SH, Raffo Grado CA, Rodriguez Venegas ME, Saavedra Gajardo VA, Westerberg Maldonado BH, Chen LL, Dong J, Guo X, Li QM, Shi B, Tang XL, Yang T, Yang WY, Zheng SX, Aschner Montoya P, Botero Lopez R, Coronel Arroyo JA, Cure CA, Gómez Medina AM, Molina DI, Perez Amador GA, Reyes Rincon A, Urina Triana MA, Valenzuela Rincon A, Vélez Pelaez S, Yupanqui Lozno H, Brabec T, Brychta T, Hasalova Zapletalova J, Havelkova J, Hejnicova K, Hola O, Hornackova M, Hrdina T, Kafkova D, Kellnerova I, Krystl T, Kutejova V, Mikulkova I, Nevrla J, Pantlikova C, Petr M, Racicka E, Sarbochova R, Skrha J, Smolenakova K, Turcinek R, Urbancova K, Vejvodova J, Vondrakova M, Zachoval R, Alt I, Ambos A, Kaasik Ü, Kiiroja K, Lanno R, Märtsin K, Past M, Vides H, Viitas L, Kantola I, Nieminen S, Perhonen M, Strand J, Strandberg T, Valle T, Clergeot A, Couffinhal T, Courreges JP, Gouet D, Moulin P, Travert F, Ziegler O, Badenhoop K, Behnke T, Bender G, Braun M, Dshabrailov J, Hamann A, Hanefeld M, Himpel-Boenninghoff A, Kamke W, Kasperk C, Luedemann J, Mayr P, Merkel M, Oerter EM, Ohlow MA, Ott P, Overhoff U, Paschen B, Remppis R, Riefflin A, Rose L, Schumm-Draeger PM, Segiet T, Strotmann HJ, Stuchlik G, Stürmer W, Thinesse-Mallwitz M, Tytko A, Wendisch U, Wurziger J, Ho AY, Kam G, Kong AP, Lam YY, Lau EY, Lee S, Siu SC, Tomlinson B, Tsang CC, Yeung VT, Dezső E, Dudás M, Földesi I, Fülöp T, Késmárki N, Koranyi L, Nagy K, Ofner P, Oroszlán T, Pécsvárady Z, Ples Z, Taller A, Agarwal P, Ambulkar S, Aravind S, Balaji V, Christopher J, Kalra S, Kesavadev J, Kudalkar H, Kumar A, Misra A, Mithal A, Mohan V, Pitale S, Ramu M, Reddy N, Shah S, Shamanna P, Sharda A, Sharma A, Shunmugavelu M, Srikanta S, Suryaprakash G, Abramov G, Adawi F, Bashkin A, Darawsha M, Fuchs S, Harman-Boehm I, Hayek T, Jaffe A, Knobler H, Minuchin O, Mosseri M, Shechter M, Shimon I, Stern N, Tsur A, Vishlitzky V, Wainstein J, Alfonsi F, Cavalot F, Del Vecchio L, Frisinghelli A, Gambardella S, Lauro D, Lembo G, Leotta S, Mondillo S, Novo S, Pedrinelli R, Piatti P, Salvioni A, Tritto I, Zavaroni DZ, Ahn KJ, Choi KM, Chung C, Han SJ, Kim DM, Kim IJ, Kim MH, Lee IK, Nam M, Park IeB, Park KS, Park TS, Park Y, Rhee EJ, Yoo SJ, Andersone I, Balode A, Eglite R, Gersamija A, Kakurina N, Jegere B, Leitane I, Pastare S, Pirags V, Stalte V, Teterovska D, Baltramonaitiene K, Barsiene L, Ceponis J, Jakuboniene N, Lasiene J, Levinger A, Sirutaviciene A, Sulskiene M, Urbanaviciene L, Valius L, Varanauskiene E, Velickiene D, Mahendran KA, Abu Hassan MR, Aziz NA, Hussein Z, Ismail IS, Kamaruddin NA, Mohamed M, Nordin Z, Nayar SK, Ramanathan GR, Sothiratnam R, Beijerbacht H, Breedveld R, Cornel JH, Den Hartog F, Hermans W, Kietselaer B, Kooy A, Lenderink T, Nierop P, Remmen J, Rojas Lingan G, Ronner E, Van der Heijden R, Van Hessen M, van Kempen W, Voors-Pette C, Westendorp I, Baker J, Benatar J, Cutfield R, Krebs J, Leikis R, Lunt H, Manning P, Scott R, Williams M, Birkeland K, Claudi T, Halvorsen S, Istad H, Karlsson T, Ossum Gronert J, Arciszewska M, Artemiuk E, Blach E, Blicharski T, Cypryk K, Dabrowska M, Górny G, Górska M, Jakubowska I, Jazwinska-Tarnawska E, Karczmarczyk A, Kitowska-Koterla J, Koltowski L, Krzyzagorska E, Pasternak D, Pentela-Nowicka J, Piesiewicz W, Przekwas-Jaruchowska M, Rajzer M, Salamon-Ferenc A, Sawicki A, Skowron T, Śmiałowski A, Tykarski A, Albota A, Alexandru C, Crisan C, Dumitrescu A, Ferariu IE, Lupusoru DA, Munteanu M, Negru D, Nicolau A, Pintiliei E, Popescu A, Serban G, Veresiu IA, Voitec M, Babenko A, Barbarash O, Bondar I, Chizhov P, Demin A, Dora S, Dreval A, Ershova O, Gratsiansky N, Ketova G, Kotelnikov M, Levashov S, Morugova T, Mustafina S, Pekarskiy S, Raskina T, Rechkova E, Samoylova Y, Sazonova O, Sherenkov A, Shilkina N, Stetsyuk O, Tretyakova T, Turova E, Valeeva F, Zadionchenko V, Dalan R, Tan RS, Tay L, Buganova I, Fabry J, Jan C, Krahulec B, Toserova E, Zak R, Zimanova J, Badat A, Bester F, Burgess L, De Jong D, Distiller L, Ellis G, Fouche L, Govender P, Govind U, Naidoo V, Nieuwoudt G, Nortje H, Rheeder P, Robertson L, Siddique N, Stapelberg AM, Trinder Y, Van Der Merwe A, Van Zyl L, Viljoen M, Wilhase A, Botella M, Civeira Murillo F, de Teresa L, Del Cañizo FJ, Extremera BG, Gimeno EJ, Martin-Hidalgo A, Morales C, Nubiola A, Rovira A, Tinahones Madueño F, Tranche S, Trescolí Serrano C, Alvarsson M, Eizyk E, Gillblad A, Johansson P, Löndahl M, Ohlsson-Önerud Å, Rautio A, Sundström U, Torstensson I, Chen JF, Chou CW, Chuang LM, Ho LT, Hsieh IC, Huang BH, Huang CL, Huang CN, Lai WT, Lo PH, Pei D, Sheu WH, Wang SY, Araz M, Bakiner O, Comlekci A, Delibasi T, Guler S, Sahin I, Sarac F, Tarkun I, Ukinc K, Yilmaz M, Abdulhakim E, Abraham P, Adamson K, Adler A, Blagden M, Bundy C, Daly M, Davies M, Deshpande M, Gillings S, Harvey P, Horvathova V, Horvathova V, Hristova D, Jaap A, Johnson A, Jones H, Kerrane J, Kilvert A, Ko T, Kumar J, Lindsay R, Litchfield J, McCrimmon R, McKnight J, Millward B, Oyesile B, Purewal T, Ravikumar C, Robinson A, Sathyapalan T, Simpson H, Thomas H, Turner W, Weaver J, Wilding J, Wiles P, Adkins K, Akpunonu B, Albu J, Anagnostis G, Anastasi L, Argoud G, Aroda V, Azizad M, Banerji MA, Bartkowiak A Jr, Bays H, Behn P, Bergenstal R, Bhargava A, Bias D, Bolster E, Buchanan P, Busch R, Chadha C, Chang M, Cheng C, Cohen A, Cohen J, Cole B, Connery L, Cooperman M, Cushman W, DAgostino R, Davies M, Dayamani P, De Lemos J, De Meireles M, Dean J, DeHart D, Detweiler R, Donovan D, Dugano-Daphnis P, Dulin M, Dunn F, Eaton C, Erickson B, Estevez R, Feinglos M, Fonseca V, Force R, Forker A, Fox D, Gabriel J, Garcia R, Garvey T, Gaudiani L, Getaneh A, Goff D, Goldberg A, Goldman S, Hairston K, Harris R, Haught W, Hidalgo H Jr, Higgins A, Houchin V, Ison R, Jacobs G, Jaffrani N, Jafry B, Kapsner P, Kaye W, Labroo A, Levinson L, Lewis S, Lillestol M, Luttrell L, Madu I, McNeill R, Merrick B, Metzger F, Nadar V, Nagelberg S, Nash S, Oparil S, Osei K, Papademetriou V, Patel N, Pedley C, Prentiss A, Radbill M, Raisinghani A, Rassouli N, Reddy R, Rees P, Rendell M, Robbins D, Rodbard H, Rohlf J, Roseman H, Rudolph L, Sadler L, Schnall A, Schramm R, Schubart U, Seneviratne T, Shanik M, Snyder H, Sorli C, Stich M, Sweeney ME, Tsao J, Ukwade P, Viswanath D, Vo A, Vogel C, Voyce S, Weintraub H, White J, Wood M, Wu P, Wysham C, Zimmerman R
- Subjects
Oral ,medicine.medical_specialty ,Heart diseases ,Glycosylated ,Administration, Oral ,heart failure ,Type 2 diabetes ,Dipeptidyl peptidase-4 inhibitor ,Kaplan-Meier Estimate ,Placebo ,Sitagliptin Phosphate ,Sitagliptin, Cardiovascular Outcomes ,chemistry.chemical_compound ,Drug Therapy ,Double-Blind Method ,Internal medicine ,Diabetes Mellitus ,medicine ,Humans ,Hypoglycemic Agents ,Glycated Hemoglobin ,Hemoglobin A, Glycosylated ,Cardiovascular Diseases ,Diabetes Mellitus, Type 2 ,Drug Therapy, Combination ,Follow-Up Studies ,Heart Diseases ,Heart Failure ,Hospitalization ,Pyrazines ,Triazoles ,Medicine (all) ,business.industry ,Semaglutide ,Hemoglobin A ,General Medicine ,ta3121 ,medicine.disease ,Surgery ,Cardiovascular diseases ,chemistry ,Sitagliptin ,Administration ,Combination ,Glycated hemoglobin ,business ,Type 2 ,Alogliptin ,medicine.drug - Abstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to-0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P
- Published
- 2015
9. Insulinoma presenting with hyperandrogenism: A case report and a literature review
- Author
-
STANCIU, I. N., PITALE, S., PRINZ, R. A., JAKATE, S., WEBB, G., STEINER, D., BRAITHWAITE, S., GORDON, D., and EMANUELE, M. A.
- Published
- 2003
10. An unusual pituitary mass presenting with panhypopituitarism and hyponatraemia
- Author
-
Pitale, S U, Lee, J M, Origitano, T, and Emanuele, N V
- Published
- 2001
11. Indigenously Developed Alpha Particle Detector Using Zns Nanostructure.
- Author
-
Sen, Shashwati, Kathyal, Vaibhav, Bhattacharya, S., Pitale, S., and Gadkari, S. C.
- Subjects
PARTICLE detectors ,ALPHA rays ,DETECTORS ,FILMMAKING - Abstract
ZnS nanoparticles were synthesized by hydrothermal technique using different precursors. The aim was to get nano particles which can be homogeneously dispersed in an organic polymer like PVP. The ZnS-PVP composite was casted to make films. These films were mounted on PMT to fabricate alpha detectors. The results shows the indigenous development of ZnS films. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. CuCrSe2: a high performance phonon glass and electron crystal thermoelectric material.
- Author
-
Bhattacharya, Shovit, Basu, Ranita, Bhatt, Ranu, Pitale, S., Singh, Ajay, Aswal, D. K., Gupta, S. K., Navaneethan, M., and Hayakawa, Y.
- Abstract
The efficient conversion of heat into electricity using a thermoelectric approach requires high performance materials with the thermoelectric figure of merit ZT ≥ 1. Here we report on bulk CuCrSe
2 , which exhibits a very high ZT ∼ 1 at 773 K. The titled compound exhibits an electrical resistivity of ∼2.8 mΩ cm, a Seebeck coefficient of ∼160 μV K−1 , together with very low thermal conductivity ∼7 mW cm−1 K−1 at 773 K. The very low thermal conductivity of bulk CuCrSe2 is attributed to phonon scattering by various sources such as (i) superionic Cu ions between the CrSe2 layers, (ii) nanoscale precipitates in the bulk and (iii) natural grain boundaries due to the layered structure of the material. This unusual combination of thermoelectric properties for CuCrSe2 suggests that it is an ideal example of the phonon glass and electron crystal approach. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
13. Growth and Optical Properties of Partially Transparent Eu Doped CaF2 ceramic.
- Author
-
Ghosh, Manoranjan, Sen, Shashwati, Pitale, S. S., Goutam, U. K., Shinde, Seema, Patra, G. D., and Gadkari, S. C.
- Subjects
DOPING agents (Chemistry) ,CALCIUM fluoride ,CERAMICS ,EUROPIUM ,PHOTOLUMINESCENCE ,X-ray diffraction ,SPECTRUM analysis - Abstract
Partially transparent ceramic of 2 at.% Eu doped CaF
2 have been grown preferentially towards [111] direction. For this purpose, Eu doped CaF2 nanoparticles (size~12 nm) obtained by a low temperature solution growth method has been pressed at 1000°C under vacuum. The preferentially grown ceramic shows 15% transparency within the visible range of spectrum. As confirmed by the X-ray diffraction result, the hot pressed ceramic exhibits reduced lattice volume than the nanopowder. It indicates Eu3+ as the dominant substituting ions at the Ca2+ sites of CaF2 lattice in the hot pressed ceramic material. It is corroborated by the photoluminescence results of hot pressed ceramic which shows strong red emission corresponding to Eu3+ sites. However, photoluminescence of nanopowder exhibits intense peak in the blue region of the spectrum which is characteristics of Eu2+ sites. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
14. Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus.
- Author
-
Camacho, P., Pitale, S., and Abraira, C.
- Subjects
- *
DIABETES , *GLYCEMIC index , *BLOOD sugar - Abstract
Diabetes mellitus is a major health problem in the world. Several clinical trials have shown that some of the major complications of diabetes mellitus can be partially prevented or delayed by intensive glycaemic control. However, there are benefits and risks in aiming for near normal blood glucose levels. Intensive glycaemic control delays the onset and progression of retinopathy, nephropathy and neuropathy. Epidemiological and observational studies have shown that cardiovascular events may be correlated with the severity and duration of diabetes mellitus, but major randomised trials have only shown weak and nonsignificant benefits of intensive glycaemic management in decreasing event rates. A modest improvement in lipid profile results from blood glucose control although, in the majority of cases, not enough to reach current targets. Detrimental effects of intensive glycaemic control include bodyweight gain and hypoglycaemia. Controversial issues in the management of patients with diabetes mellitus include the unproven increase in cardiovascular morbidity from sulphonylureas and hyperinsulinaemia, and the still unknown long term effects of newer oral antihyperglycaemic agents alone or in combination with traditional therapies (such as sulphonylureas and metformin). It is important to individualise management in setting glycaemic goals. Control of cardiovascular risk factors through blood pressure and lipid control and treatment with aspirin (acetylsalicylic acid) and ACE inhibitors have consistently shown benefits in the prevention of both macro- and microvascular complications in patients with diabetes mellitus; these measures deserve priority. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
15. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
- Author
-
Pitale, Shailesh U., Abraira, Carlos, Emanuele, Nicholas V., McCarren, Madeline, Henderson, William G., Pacold, Ivan, Bushnell, David, Colwell, John A., Nuttall, Frank Q., Levin, Seymour R., Sawin, Clark T., Comstock, John P., Silbert, Cynthia K., Pitale, S U, Abraira, C, Emanuele, N V, McCarren, M, Henderson, W G, Pacold, I, and Bushnell, D
- Subjects
DIABETES complications ,BLOOD sugar monitoring ,REGULATION of heart contraction - Abstract
Objective: The Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM) was a multicenter randomized prospective study of 153 male type 2 diabetic patients to assess the ability to sustain clinically significant glycemic separation between intensive and standard treatment arms. A trend toward an excess of combined cardiovascular events in the intensive treatment arm of this trial was reported earlier. The present analysis was done to evaluate the effect of 2 years of intensive glycemic control on the left ventricular (LV) function.Research Design and Methods: The patients were randomized to intensive step treatment with insulin alone or with sulfonylurea (intensive treatment arm [INT], n = 75) or to standard once-daily insulin injection (standard treatment arm [STD], n = 78) treatment. A total of 136 patients (standard treatment arm [STD], n = 70; INT, n = 66) had radionuclide ventriculography at entry and at 24 months for the assessment of LV function.Results: There was no difference in the mean LV ejection fraction (at entry: STD 57.1+/-9.51%; INT 58.1+/-8.7%; at 24 months: STD 57.3+/-10.8%, INT 59.5+/-10.7%), peak filling rate (at entry: STD 2.6+/-0.7 end diastolic volume per second, INT 2.4+/-0.8 end diastolic volume per second; at 24 months: STD 2.7+/-1.0 end diastolic volume per second, INT 2.5+/-0.7 end diastolic volume per second), or time to peak filling rate (at entry: STD 195.3+/-69.5 ms, INT 185.6 +/-62.4 ms; at 24 months: STD 182.6+/-64.8 ms, INT 179.2+/-61.2 ms) between the 2 treatment arms. A subgroup analysis of 104 patients (STD, n = 53; INT, n = 51) that omitted individuals with intervening cardiac events/revascularization or a change in cardioactive medications also showed no difference in the LV function at entry and at 24 months between the 2 groups. Abnormal LV ejection fraction at baseline predicted cardiac events (interval between cardiac beats [RR] = 2.5).Conclusions: Two years of intensive glycemic control does not affect the LV systolic or diastolic function in patients with type 2 diabetes. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
16. SELF ASSESSMENT QUESTIONS: An unusual pituitary mass presenting with panhypopituitarism and hyponatraemia.
- Author
-
Pitale, S. U., Lee, J. M., Origitano, T., and Emanuele, N. V.
- Subjects
- *
PITUITARY diseases , *RESPIRATORY infections , *LUMBAR puncture , *JUVENILE diseases , *TOMOGRAPHY , *VISUAL fields - Abstract
This article studies the case of a 72 year old Asian man was transferred to our institution for work-up of hyponatraemia and an intrasellar mass. The patient had been exposed to ill children and reported symptoms of upper respiratory tract infection a week before presentation. Lumbar puncture findings were normal. Computed tomography of the head done at that point showed a 2.1 cm sellar mass with suprasellar extension, elevating the optic chiasm. The neuro-ophthalamic evaluation revealed bitemporal visual field defects with no papilloedema.
- Published
- 2001
- Full Text
- View/download PDF
17. LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA and GOAL Registries.
- Author
-
Deshmukh V, Chaudhury T, Chadha M, Chawla M, Mukherjee S, Pitale S, Basu D, Gadekar A, Menon S, Trivedi C, Salvi V, Ramakrishnan S, and Goyal G
- Abstract
Introduction: Real-world evidence on insulin glargine 100 U/ml (Gla-100) initiation in Indian type 2 diabetes mellitus (T2DM) individuals is limited. The present study aimed to evaluate the effectiveness of Gla-100 in insulin-naïve T2DM participants from India., Methods: This post hoc analysis includes real-world data of insulin-naïve Indian participants with T2DM who started Gla-100 treatment in two Asian registries: FINE ASIA and GOAL. Changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, insulin dose, and incidence of hypoglycemia from baseline to 6 months were assessed., Results: A total of 955 participants with T2DM were identified and analyzed. The mean [standard deviation (SD)] age and duration of diabetes were 54.7 (9.8) years and 9.8 (6.3) years, respectively. Mean HbA1c and FPG were significantly reduced after 6 months of Gla-100 treatment [- 2.07 (1.4) %; - 94.4 (65.2) mg/dl, respectively]. HbA1c targets of < 7.0% and < 7.5% were achieved by 292 (30.6%) and 589 (61.7%) study participants, respectively. The overall incidence of hypoglycemia was low (n = 52; 5.4%); only two participants (0.2%) reported severe hypoglycemia. Insulin was titrated with a mean (SD) increment of 2.5 (5.6) U/day after 6 months, leading to a mean Gla-100 dose of 18.2 (8.9) U/day. Mean body weight remained unchanged from baseline to 6 months (- 0.1 kg)., Conclusion: In routine clinical practice, Gla-100 significantly improved glycemic parameters after 6 months of treatment with a low risk of hypoglycemia and no weight change in participants with T2DM., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
18. Clinical and Demographic Profile of Diabetic Patients from Central India - Results from Diabetes Registry.
- Author
-
Pitale S, Sahasrabuddhe A, Gandhi P, Joshi P, Sakhare A, Balankhe N, Khobragade S, Sengupta S, Ambulkar S, Ganeriwal M, Shembalkar J, and Naidu S
- Abstract
Objective: This study was done to analyse the demographic profile and presentation of diabetes in Central India., Design: Data was collected for this cross-sectional study from an electronic diabetes registry from 2014 to 2019. Demographic details, patient history and presence or absence of co-morbid conditions, duration of diabetes, age of onset of diabetes, drug history, personal history, presence of micro and/or macrovascular complications and investigations done were obtained., Statistical Analysis: The association between each factor and the outcome was studied in terms of prevalence ratio (PR) using the R-3.0.0 programming (R Foundation for Statistical Computing, Vienna, Austria) language. Statistical significance was evaluated at a 5% level., Results: Among 12,434 patients, 54.95% were below 50 years and 45.05% were above 50 years. 50.21% were females and 49.79% were males. The mean age was 47.49 ± 14.78 years and the mean body mass index (BMI) was 26.85 ± 5.19 kg/m
2 with 62.29% of obese patients (>25 kg/m2 ). The mean overall duration of diabetes was 7.64 ± 7.63 years. Mean Glycosylated Haemoglobin (HbA1c) in patients <=50 years was 8.60 ± 2.63 and 8.90 ± 1.91 for over 50. 65.59% had uncontrolled blood sugars. 25.19% of patients had hypertension and 18.1% had dyslipidaemia. Coronary artery disease (CAD), nephropathy, neuropathy and retinopathy were observed in 21.49%, 9.60%, 33.65% and 14.65%, respectively. The adjusted PR of cardiovascular disease (CVD) was 5.374 times higher for patients over 50 ( P < 0.0001); 3.775 times higher for males ( P < 0.0001), 1.64 times higher for patients with BMI >25 kg/m2 ( P < 0.0001) and 3.643 times higher in hypertensive cases ( P < 0.0001). Similar associations were observed with nephropathy, neuropathy and retinopathy., Conclusion: From a large population study on diabetes, it was found a majority of the type 2 diabetes mellitus (T2DM) cases (65%) are sub-optimally controlled with HbA1c levels. Also, microvascular complications were related to the sub-optimal glycaemic control, but not the macro-vascular complications., Competing Interests: There are no conflicts of interest., (Copyright: © 2022 Indian Journal of Endocrinology and Metabolism.)- Published
- 2022
- Full Text
- View/download PDF
19. Basal Insulin Titration: Moving Towards a More Patient-Centric Approach with Gla-100 in India.
- Author
-
Madhu SV, Neelaveni K, Pitale S, Somani S, Pandey AK, Kalra P, Ceaser R, Mohanasundaram S, and Mohan V
- Subjects
- Asia, Blood Glucose, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents, India, Insulin Glargine, Diabetes Mellitus, Type 2 drug therapy
- Abstract
Owing to the progressive nature of the disease, patients with type 2 diabetes mellitus (T2DM) eventually require adjustment or titration of insulin doses to achieve the desired glycemic control. Titration inertia, or the inability to dose-titrate, is one of the key barriers to optimized insulin therapy and is common in Asian countries such as India. Simple and effective titration algorithms involving the use of basal insulin, which has the lowest hypoglycemia risk, that can be individualized by physicians and easily followed by patients aid in tackling titration inertia. In this context, insulin glargine 100 U/mL (Gla-100) appears to be the ideal insulin to overcome titration inertia, owing to its low risk of hypoglycemia and effective glycemic control. Different guidelines recommend the use of basal insulin, such as Gla-100, and encourage a patient-centric approach for dose titration. Although the effective implementation of the patient-centric approach in India is challenging, it is nevertheless achievable., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2020
20. Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS).
- Author
-
Ramachandran A, Jain SM, Mukherjee S, Phatak S, Pitale S, Singh SK, Agrawal N, Majumdar A, Deshpande N, Jhulka S, Minakshisundaram S, Chawla M, Lodha S, Maheshwari A, Makkar BM, Rao S, Shah P, Ghosh R, Mohanasundaram S, Menon S, Chodankar D, Kanade V, and Trivedi C
- Abstract
Objective: To assess the real-world management practices of subjects with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) in India., Methods: This cross-sectional study was conducted between 7 March 2016 and 15 May 2016 in India as part of the seventh wave (2016) of the International Diabetes Management Practices Study (IDMPS). Adult subjects with T1DM or T2DM visiting physicians during a 2-week recruitment period were included., Results: A total of 55 physicians included 539 subjects who met eligibility criteria. Of 495 subjects with T2DM, 303 were treated with oral glucose lowering drugs (OGLDs) only, 158 were treated with OGLD + insulin, and 27 received insulin only. Among 44 subjects with T1DM receiving insulin, 13 (29.5%) were also treated with OGLD therapy. The most commonly used insulin regimens were basal alone (69/184; 37.5%) and premixed alone (63/184; 34.2%) in subjects with T2DM, and basal + prandial insulin (24/44; 54.5%) in subjects with T1DM. Proportions of subjects achieving glycemic targets were low [glycated haemoglobin (HbA1c) <7%: T1DM = 7.3% (3/44), T2DM = 25.2% (106/495); as targeted by the treating physician: T1DM = 31.8% (14/44), T2DM = 32.1% (59/185); global target: T1DM = 4.8% (2/42) and T2DM = 1.7% (8/482)]. In subjects with T2DM, HbA1c <7% was noted in 11/22 subjects receiving insulin only and 76/260 receiving only OGLDs. Lack of experience in self-managing insulin dosing, poor diabetes education and failure to titrate insulin dosages were the main reasons for non-achievement of glycemic targets., Conclusion: Timely insulinization, education and empowerment of people with diabetes may help improve glycemic control in India., Competing Interests: Conflict of interest statement: Shunmugavelu Minakshisundaram was a study investigator and received an honorarium during the period in which the study was conducted. Anirban Majumdar is a consultant and/or speaker for Eli Lilly, Novo Nordisk India, Sanofi India Limited, and Wockhardt India Ltd. that market different insulin preparations. MC is a member of the speaker bureau for Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, USV, IPCA, Biocon, and Cipla. SMJ has been associated with Sanofi, Novo, Eli Lilly, Novartis, Boehringer-Ingelheim, and AstraZeneca for various trials and educational initiatives. AR, Sagarika Mukherjee, Sanjeev Phatak, Shailesh Pitale, NA, ND, SJ, SL, Anuj Maheshwari, BMM, SR, PS, and SKS declared no conflict of interest. RG, Senthilnathan Mohanasundaram, Shalini Menon, DC, VK, CT are employees of Sanofi., (© The Author(s), 2020.)
- Published
- 2020
- Full Text
- View/download PDF
21. Organic-Inorganic Composite Films Based on Gd 3 Ga 3 Al 2 O 12 :Ce Scintillator Nanoparticles for X-ray Imaging Applications.
- Author
-
Sen S, Tyagi M, Sharma K, Sarkar PS, Sarkar S, Basak CB, Pitale S, Ghosh M, and Gadkari SC
- Abstract
Organic-inorganic nanocomposite self-standing films of Gd
3 Ga3 Al2 O12 (GGAG) uniformly dispersed in poly(methyl methacrylate) (PMMA) and polystyrene polymer are prepared for radiography application. GGAG:Ce nanoscintillator has been chosen because of its high light output and fast decay time. The nanopowder of GGAG is synthesized by coprecipitation method and dispersed in the polymer matrix by a simple blending technique. The nanocomposite films of thickness in the range of 150-450 μm with a very high inorganic content is achieved by this technique. These films are characterized by their uniformity, optical absorption, photoluminescence, and radioluminescence. These films are further tested for their application in radiography by recording X-ray images using a commercially available charge-coupled device camera. A resolution of 10 lp/mm is obtained using GGAG:PMMA composite film with 50% loading, confirming their application in imaging devices.- Published
- 2017
- Full Text
- View/download PDF
22. Cardiac Diastolic Dysfunction and Regional Body Fat Distribution in Insulin Resistant Peripubertal Obese Males.
- Author
-
Sahasrabuddhe AV, Pitale SU, Dhoble, Shivalkar J, and Sagdeo MM
- Subjects
- Adolescent, Biomarkers blood, Body Fat Distribution, Child, Humans, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular physiopathology, Insulin Resistance, Male, Obesity blood, Obesity diagnosis, Obesity physiopathology, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left physiopathology, Ventricular Function, Left physiology, Diastole physiology, Hypertrophy, Left Ventricular etiology, Insulin blood, Obesity complications, Ventricular Dysfunction, Left etiology
- Abstract
Background: To evaluate presence of diastolic dysfunction in obese peripubertal males (8-18 years of age). To correlate diastolic dysfunction with insulin resistance, insulin levels and omental and epicardial fat., Methods: Obese males (n=46) and age matched healthy lean controls (n=50) in the age group of 8-18 years were included in this study. Anthropometric measurements were recorded. Investigations done: Fasting blood sugar and serum insulin levels, lipid profile, 2-D Echocardiography to assess left ventricular diastolic function and epicardial fat, abdominal CT scan to measure omental fat and ultrasound for NAFLD., Results: Isovolumetric relaxation time (IVRT) above 100 msec seen in 18/46, E/A ratio of 0.75 seen in 4/46 cases. Left ventricular mass > 125gm seen in 10/46 cases. All the left ventricular diastolic function parameters were within normal range in controls. Significant difference in LVM (p=0.00099), LVPW(d) (p=0.0018), IVS(d) (p=0.007), E/A ratio (p=0.043), epicardial fat (p=0.0000) were seen in cases as compared to controls. Correlation of visceral fat with HOMA-IR, insulin levels and left ventricular diastolic parameters in cases was as follows HOMA vs omental fat (p=0.0008), Insulin vs omental fat (p=0.0015), E/A vs omental fat (p=0.015), LVM vs omental fat (p=0.0000), IVRT vs omental fat (p-=0.005). HOMA vs epicardial fat (p=0.0000), insulin vs epicardial fat (p=0.0000), E/A vs epicardial fat (p=0.09), LVM vs epicardial fat (p=0.006), IVRT vs epicardial fat (p=0.011)., Conclusions: Left ventricular hypertrophy and diastolic derangements start early in obese peripubertal males with positive correlation between left ventricular diastolic dysfunction and HOMA-IR and insulin levels. Epicardial fat mass and visceral fat show positive correlation with diastolic dysfunction.
- Published
- 2016
23. Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015.
- Author
-
Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, Chandalia HB, Chowdhury S, Jothydev K, Kumar PK, V MS, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundaram A, Unnikrishnan AG, and Wangnoo SK
- Abstract
As injectable therapies such as human insulin, insulin analogs, and glucagon-like peptide-1 receptor agonists are used to manage diabetes, correct injection technique is vital for the achievement of glycemic control. The forum for injection technique India acknowledged this need for the first time in India and worked to develop evidence-based recommendations on insulin injection technique, to assist healthcare practitioners in their clinical practice.
- Published
- 2015
- Full Text
- View/download PDF
24. A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis.
- Author
-
Pitale S, Thomas M, Rathi G, Deshmukh V, Kumar P, Reddy S, Shetty N, Kakar A, Babhulkar S, Mody B, Chacko J, Acharya S, Joglekar S, Halbe V, Kravitz BG, Waterhouse B, Nino AJ, and Fitzpatrick LA
- Abstract
Introduction: Osteoporosis is a serious condition affecting up to 50% of Indian postmenopausal women. Denosumab reduces bone resorption by targeting the receptor activator of nuclear factor-κB ligand. This study assessed the efficacy and safety of denosumab in Indian postmenopausal women with osteoporosis., Materials and Methods: In this double-blind, multicenter, phase 3 study, 250 Indian postmenopausal women aged 55 to 75 years (T-score <-2.5 and >-4.0 at the lumbar spine or total hip; serum 25(OH) D levels ≥20 ng/mL) were randomized to receive one subcutaneous dose of denosumab 60 mg or placebo. All subjects received oral calcium ≥1000 mg and vitamin D3 ≥ 400 IU daily. The primary end point was mean percent change in bone mineral density (BMD) at the lumbar spine from baseline to Month 6. Secondary end points included mean percent change from baseline in BMD at total hip, femoral neck, and trochanter at Month 6 and median percent change from baseline in bone turnover markers at Months 1, 3, and 6., Results: Total 225 subjects (denosumab = 111, placebo = 114) completed the six-month study. Baseline demographics were similar between groups. A 3.1% (95% confidence interval, 1.9%, 4.2%) increase favoring denosumab versus placebo was seen for the primary end point (P < 0.0001). Denosumab demonstrated a significant treatment benefit over placebo for the secondary end points. There were no fractures or withdrawals due to adverse events., Conclusions: Consistent with results from studies conducted in other parts of the world, denosumab was well tolerated and effective in increasing BMD and decreasing bone turnover markers over a six-month period in Indian postmenopausal women.
- Published
- 2015
- Full Text
- View/download PDF
25. Cord blood levels of insulin and glucose in full-term pregnancies.
- Author
-
Sahasrabuddhe A, Pitale S, Raje D, and Sagdeo MM
- Subjects
- Adult, Birth Weight physiology, Female, Fetal Blood chemistry, Humans, Insulin Resistance, Pilot Projects, Reference Values, Blood Glucose metabolism, Fetal Blood metabolism, Insulin blood, Pregnancy blood
- Abstract
Objectives: This pilot study was undertaken to know the normal values of cord blood insulin and glucose levels in full-term normal pregnancies and pregnancies complicated with maternal conditions like pregnancy induced hypertension (PIH), thyroid dysfunction and Gestational Diabetes Mellitus (GDM)., Method: Full-term pregnancies from Ketkar maternity hospital, Nagpur, since January 2011 were included in the study. A total of 121 cases have been studied. Demographic and clinical data of the included cases was obtained from the hospital records. Cord blood sample was analyzed for serum insulin and plasma glucose levels. These two metabolic parameters were used to derive (Homeostatic Model Assessment) HOMA index for insulin resistance and Glucose-to-Insulin Ratio (GIR). The data on physical and metabolic parameters was analyzed using parametric statistical significance tests for means and correlation using R-package, Result: The difference in glucose concentration was found insignificant (p > 0.05) across complicated and uncomplicated pregnancies. However, for the comparison 'no complications' vs PIH, the insulin levels differed significantly at 10% (p = 0.09). Accordingly, for the same comparison, GIR also indicated significant difference at 10% (p = 0.07) between the two maternal groups. The mean cord blood glucose level was higher in PIH cases compared to un-complicated maternal cases; while the mean insulin level was lower in PIH cases as compared to non-complicated cases, as a result mean GIR was higher in PIH category. HOMA did not show significant difference in any comparison. The relationship of metabolic parameters and the derived variables with birth weight in the two maternal groups showed insignificant relationships between birth weight and dependent variables (p > 0.05)., Conclusion: The levels of insulin and glucose in normal full-term pregnancies was found to be 6.75 +/- 2.96 mIU/ ml and 91.69 +/- 27.05 mg/dl respectively with GIR of 13.57 +/- 7.47 and HOMA 1.57 +/- 0.83. Low serum insulin levels with normal or high GIR was noted in pregnancies complicated by PIH. Insulin resistance as measured by HOMA IR is increased in patients with hypothyroidism. Hyperinsulinemia is seen in babies with birth weight less than 2.5 kg or more than 3.5 kg.
- Published
- 2013
26. Forum for injection techniques, India: the first Indian recommendations for best practice in insulin injection technique.
- Author
-
Kalra S, Balhara YP, Baruah MP, Chadha M, Chandalia HB, Chowdhury S, Kumar KM, Modi S, Pitale S, Shukla R, Sahay R, Sundaram A, Unnikrishnan AG, and Wangnoo SK
- Abstract
Advances in the treatment of diabetes have led to an increase in the number of injectable therapies, such as human insulin, insulin analogues, and glucagon-like peptide-1 analogues. The efficacy of injection therapy in diabetes depends on correct injection technique, among many other factors. Good injection technique is vital in achieving glycemic control and thus preventing complications of diabetes. From the patients' and health-care providers' perspective, it is essential to have guidelines to understand injections and injection techniques. The abridged version of the First Indian Insulin Injection technique guidelines developed by the Forum for Injection Technique (FIT) India presented here acknowledge good insulin injection techniques and provide evidence-based recommendations to assist diabetes care providers in improving their clinical practice.
- Published
- 2012
- Full Text
- View/download PDF
27. Genetic variety of bovine viral diarrhea virus 1 strains isolated from sheep and goats in India.
- Author
-
Mishra N, Pitale SS, Rajukumar K, Prakash A, Behera SP, Nema RK, and Dubey SC
- Subjects
- Animals, Cattle, Diarrhea Virus 1, Bovine Viral classification, Goats, India, Molecular Sequence Data, Pestivirus Infections virology, Phylogeny, Sheep, Diarrhea Virus 1, Bovine Viral genetics, Diarrhea Virus 1, Bovine Viral isolation & purification, Genetic Variation, Goat Diseases virology, Pestivirus Infections veterinary, Sheep Diseases virology
- Abstract
Unlabelled: Antigenic and genetic typing of pestiviruses isolated from Indian sheep and goats was carried out. Testing of 1777 sheep and 1026 goat blood samples collected between 2004 and 2008 resulted in isolation of twelve pestiviruses, seven from sheep and five from goats. All of them were antigenically typed as bovine viral diarrhea virus 1 (BVDV-1). Both the partial 5ʹ-UTR and entire non-structural autoprotease (Npro) gene of the pestiviruses were amplified by RT-PCR and sequenced. The phylogenetic analysis confirmed all twelve sheep and goat pestiviruses as BVDV-1 and they were further classified into two subtypes, BVDV-1b (seven) and BVDV-1c (five). This is for the first time that BVDV-1c was detected in sheep and goats. However, no association between the subtype and geographic area of origin was observed. Although closely related, BVDV-1b and BVDV-1c isolates of sheep and goats were placed in a different clade than previously reported Indian BVDV-1b/BVDV-1c isolates. This study confirmed widespread prevalence of BVDV-1 in Indian sheep and goats that has significance in the epidemiology of bovine viral diarrhea., Keywords: bovine viral diarrhea virus; BVDV-1; goat; Npro; genetic typing; sheep; 5ʹ-UTR.
- Published
- 2012
- Full Text
- View/download PDF
28. Fetal origin of vascular aging.
- Author
-
Pitale S and Sahasrabuddhe A
- Abstract
Aging is increasingly regarded as an independent risk factor for development of cardiovascular diseases such as atherosclerosis and hypertension and their complications (e.g. MI and Stroke). It is well known that vascular disease evolve over decades with progressive accumulation of cellular and extracellular materials and many inflammatory processes. Metabolic syndrome, obesity and diabetes are conventionally recognized as risk factors for development of coronary vascular disease (CVD). These conditions are known to accelerate ageing process in general and vascular ageing in particular. Adverse events during intrauterine life may programme organ growth and favour disease later in life, popularly known as, 'Barker's Hypothesis'. The notion of fetal programming implies that during critical periods of prenatal growth, changes in the hormonal and nutritional milieu of the conceptus may alter the full expression of the fetal genome, leading to permanent effects on a range of physiological.
- Published
- 2011
- Full Text
- View/download PDF
29. Pathogenicity of an Indian isolate of bovine viral diarrhea virus 1b in experimentally infected calves.
- Author
-
Galav V, Mishra N, Dubey R, Rajukumar K, Pitale SS, Shrivastav AB, and Pradhan HK
- Subjects
- Animals, Antibodies, Viral blood, Bovine Virus Diarrhea-Mucosal Disease blood, Bovine Virus Diarrhea-Mucosal Disease immunology, Bovine Virus Diarrhea-Mucosal Disease pathology, Cattle, Diarrhea Virus 1, Bovine Viral classification, Fever, Gastrointestinal Tract pathology, India, Kidney pathology, Lymph Nodes pathology, Male, RNA, Viral blood, Testis pathology, Bovine Virus Diarrhea-Mucosal Disease virology, Diarrhea Virus 1, Bovine Viral pathogenicity
- Abstract
The aim of this study was to determine the pathogenicity of an Indian bovine viral diarrhea virus (BVDV) 1b isolate in 7-9-months-old male calves. Infected (four) and control (two) calves were bled at three days interval for hematological, virological and serological studies until day 27. All infected calves developed respiratory illness, biphasic pyrexia, mild diarrhea, leucopenia and mild thrombocytopenia. Viraemia was demonstrated between 3 and 15dpi and the infected calves seroconverted by 15dpi. Prominent kidney lesions were endothelial cell swelling, proliferation of mesangial cells and podocytes leading to glomerular space obliteration. Degeneration and desquamation of cells lining seminiferous tubules were observed in two infected calves. Consolidation of lungs with interstitial pneumonia, mild gastroenteritis and systemic spread were also evident. It was concluded that Indian BVDV isolate induced moderate clinical disease in calves and glomerulonephritis resulting from acute BVDV infection was observed for the first time.
- Published
- 2007
- Full Text
- View/download PDF
30. Genetic and antigenic characterization of bovine viral diarrhea virus type 2 isolated from Indian goats (Capra hircus).
- Author
-
Mishra N, Dubey R, Rajukumar K, Tosh C, Tiwari A, Pitale SS, and Pradhan HK
- Subjects
- 5' Untranslated Regions chemistry, 5' Untranslated Regions genetics, Amino Acid Sequence, Animals, Antibodies, Monoclonal immunology, Antibodies, Viral blood, Antigens, Viral analysis, DNA, Viral chemistry, DNA, Viral genetics, Diarrhea Virus 2, Bovine Viral immunology, Goat Diseases epidemiology, Goats, India epidemiology, Neutralization Tests veterinary, Pestivirus Infections epidemiology, Pestivirus Infections virology, Phylogeny, Reverse Transcriptase Polymerase Chain Reaction veterinary, Diarrhea Virus 2, Bovine Viral classification, Diarrhea Virus 2, Bovine Viral genetics, Goat Diseases virology, Pestivirus Infections veterinary
- Abstract
Recent studies have shown that bovine viral diarrhea virus (BVDV) type 1 is widely prevalent in Indian cattle. In a surveillance of randomly collected 562 blood samples from seven states during 2004-2006, BVDV type 2 was detected in two native Indian goats by nested reverse transcription polymerase chain reaction (nRT-PCR). The virus isolated from them was classified antigenically as BVDV 2 on the basis of virus neutralization test and reactivity with monoclonal antibodies. Phylogenetic analysis of three different genomic regions, 5' un-translated region (5' UTR), E(rns) structural coding region and NS5B nonstructural coding region typed Indian goat isolate as BVDV 2a having close similarity with strains from North America and Europe suggesting its probable introduction through trade. It was placed in a separate clade within the 2a branch having unique mutations in E(rns) and NS5B region. This is the first report of BVDV 2 in India and only second time recorded in goat species. The isolation of BVDV 2 from goat warrants intensive surveillance in cattle and sheep.
- Published
- 2007
- Full Text
- View/download PDF
31. Genetic analysis of indian bovine viral diarrhea virus 1 isolates in N(pro) and entire gene region coding structural proteins.
- Author
-
Mishra N, Vilcek S, Jain P, Pitale SS, and Pradhan HK
- Subjects
- Amino Acid Sequence, Animals, Cattle, Diarrhea Virus 1, Bovine Viral classification, Molecular Sequence Data, Mutation, Viral Proteins chemistry, Viral Structural Proteins chemistry, Diarrhea Virus 1, Bovine Viral genetics, Viral Proteins genetics, Viral Structural Proteins genetics
- Abstract
Three Indian Bovine viral diarrhea virus 1 (BVDV-1) isolates were analyzed at genetic level in N(pro) (viral autoprotease) and entire gene region coding structural proteins, namely capsid (C) protein, E(rns), and envelope proteins E1 and E2. All these isolates were found to be of b subtype based on the entire 504 nt region of N(pro) and 1119 nt region of E2. However, in comparison with other isolates of this subtype, they were allocated inside the BVDV-1 subtype b cluster to a separate clade with a longer distance. Of six cysteine residues in N(pro) only three were totally conserved in all three isolates. The isolates showed 94.9-99.3% and 92.2-99.0% identities for the entire C-E2 gene region at nucleotide and amino acid levels, respectively. The lowest identity values (88.5-91.7%) were observed for E2 amino acid sequences. The identity of the isolates with Osloss, a reference BVDV-1 subtype b strain, was in the range of 82.1-89.9% for nucleotide and 78.6-89.2% for amino acid sequences in the C-E2 region. The N(pro)/C and E(rns)/E1 cleavage sites were highly conserved. The C/E(rns) and E1/E2 cleavage sites were more conserved from the N-end of E(rns) and the C-end of El, respectively. These findings suggest that some unique mutations have occurred in the described Indian BVDV-1 isolates, though they all belong to the BVDV-1 subtype b.
- Published
- 2006
32. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus.
- Author
-
Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, and Abraira C
- Subjects
- Adult, Aged, Feasibility Studies, Glycated Hemoglobin metabolism, Humans, Male, Middle Aged, Prospective Studies, Surveys and Questionnaires, Treatment Outcome, Blood Glucose drug effects, Diabetes Complications, Diabetes Mellitus, Type 2 drug therapy, Glycated Hemoglobin drug effects, Health Status, Hypoglycemic Agents therapeutic use, Quality of Life
- Abstract
Objective: The Veterans Affairs Cooperative Study in Diabetes Mellitus Type 2 Feasibility Trial (VA CSDM) studied standard and intensive glycemic treatment groups, achieving and maintaining for 27 months a difference in HbA1c of 2.1% (9.2% vs. 7.1%, respectively). A substudy planned in advance examined health status as assessed by a health status questionnaire obtained at baseline and 24 months., Design and Methods: A randomized, prospective trial was carried out at five VA Medical Centers from 1990 to 1993. The sample involved 153 male veterans 40-69 years of age and with diabetes duration of 8+/-4 years, who were suboptimally controlled with standard glucose lowering treatment. The participants were randomized to intensive and standard treatment groups. In addition to a variety of indicators of glycemic control and complications, health-related qualify of life data were assessed using a 20-question version of the Medical Outcome Study instrument. Scores were evaluated at baseline and 24 months for changes between the treatment groups., Results: The two groups were similar at baseline with respect to age, duration of diabetes, complications, comorbidities, and reported physical activity. The intensive treatment group had more frequent, mandatory self-glucose monitoring (vs. occasional measurement in the standard) and received two or more daily insulin injections (only one in the standard). This group had three times the number of clinic visits and 10-fold higher reported incidence of mild/moderate hypoglycemia. There were no significant changes in the health status over time in either the standard or intensive treatment groups, nor was there a difference between the two groups., Conclusions: Intensive glucose control in advanced Type 2 diabetes mellitus (DM) has no effect on health status over 2 years. The successful lowering of glycemia does not improve health-related quality of life nor do the increased demands of an intensive therapy regimen worsen it.
- Published
- 2005
- Full Text
- View/download PDF
33. Testosterone treatment enhances regional brain perfusion in hypogonadal men.
- Author
-
Azad N, Pitale S, Barnes WE, and Friedman N
- Subjects
- Aged, Cognition physiology, Gyrus Cinguli blood supply, Gyrus Cinguli diagnostic imaging, Humans, Hypogonadism diagnostic imaging, Male, Memory physiology, Mesencephalon blood supply, Mesencephalon diagnostic imaging, Middle Aged, Serotonin physiology, Tomography, Emission-Computed, Single-Photon, Cerebrovascular Circulation drug effects, Gonadal Steroid Hormones therapeutic use, Hypogonadism drug therapy, Hypogonadism physiopathology, Testosterone therapeutic use
- Abstract
The positive effect of testosterone replacement therapy on psychosocial well-being in hypogonadal men has been demonstrated by various psychometric tests. However, there is no report available that objectively demonstrates the effect of testosterone on the function of the central nervous system in men. In this report we studied cerebral perfusion in seven hypogonadal men on testosterone replacement therapy. The blood perfusion to the central nervous system was assessed using single-photon emission-computed tomography. (99 m)Tc-hexamethyl-propylene-amine oxime crosses the blood brain barrier and localizes in brain tissue, depending on the intensity of the local blood flow. Psychosocial well-being was assessed with an Androgen Deficiency in Aging Men questionnaire. The study demonstrated that testosterone replacement enhanced cerebral perfusion in midbrain and superior frontal gyrus (Brodman area 8) at 3-5 wk of treatment. At 12-14 wk the study continued to show increased perfusion in midbrain in addition to the appearance of a new activated region in the midcingulate gyrus (Brodman area 24). The results of this study provide objective evidence that testosterone and /or its metabolites increased cerebral perfusion in addition to the improvement in cognitive function.
- Published
- 2003
- Full Text
- View/download PDF
34. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism.
- Author
-
Camacho P, Gordon D, Chiefari E, Yong S, DeJong S, Pitale S, Russo D, and Filetti S
- Subjects
- Adenocarcinoma, Follicular complications, Adenocarcinoma, Follicular pathology, Female, Humans, Hyperthyroidism etiology, Hyperthyroidism pathology, Middle Aged, Thyroid Neoplasms complications, Thyroid Neoplasms pathology, Adenocarcinoma, Follicular genetics, Hyperthyroidism genetics, Point Mutation, Receptors, Thyrotropin genetics, Thyroid Neoplasms genetics
- Abstract
Hot nodules are rarely found to be carcinomas. We report a case of a nonmetastatic follicular carcinoma that presented as a hot nodule that was causing hyperthyroidism. A base substitution (ATC for TTC) was found in codon 486 of the TSH receptor gene and this resulted in the substitution of an isoleucine for a phenylalanine in the first extracellular loop of the receptor. This was absent in the deoxyribonucleic acid from the surrounding normal thyroid tissue indicating its somatic origin. This mutation, which was previously reported to activate both cyclic adenosine monophosphate and the inositol phosphate-diacylglycerol cascades, may have been responsible for the constitutive activation of the thyrotropin receptor and resulting hyperfunction of this follicular carcinoma.
- Published
- 2000
- Full Text
- View/download PDF
35. Fine-needle aspiration of the thyroid: rate and causes of cytohistopathologic discordance.
- Author
-
Bakhos R, Selvaggi SM, DeJong S, Gordon DL, Pitale SU, Herrmann M, and Wojcik EM
- Subjects
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Diagnostic Errors standards, Diagnostic Errors statistics & numerical data, False Negative Reactions, False Positive Reactions, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Thyroid Diseases pathology, Thyroid Neoplasms pathology, Biopsy, Needle, Thyroid Gland pathology
- Abstract
Fine-needle aspiration (FNA) of the thyroid gland is a widely utilized, sensitive, specific, and cost-effective method for the evaluation of thyroid nodules. The purpose of this study was to evaluate the accuracy of thyroid FNA and causes of cytohistological discordance in our institution. Six hundred twenty-five thyroid FNAs obtained from 503 females (mean age, 54) and 122 males (mean age, 51) in whom histopathologic follow-up material was available for review, were analyzed. FNAs were classified as: nondiagnostic, negative, intermediate, and positive for malignancy, and the histopathologic material was categorized as benign or malignant. The review revealed 93% sensitivity and 96% specificity for the FNA diagnoses. The FNA results were diagnostic in 87%, indeterminate in 6%, and nondiagnostic in 7% of the cases. Cytohistologic correlation was achieved in 88% of the cases. The false-negative rate was 4% and the false-positive rate was 8%. The most common pitfalls for false-negative diagnoses consisted of suboptimal material and underdiagnosis of papillary carcinoma due to cystic degeneration. The most common pitfall for false-positive cases was overdiagnosis of follicular neoplasms. Our study confirmed that FNA of thyroid nodules can be performed with high sensitivity and specificity by experienced clinicians or pathologists. The application of strict specimen adequacy rules for FNA interpretation is likely to decrease the rate of false-negative and false-positive diagnoses., (Copyright 2000 Wiley-Liss, Inc.)
- Published
- 2000
- Full Text
- View/download PDF
36. Brain metastases from medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 2A.
- Author
-
Pitale SU, Melian E, Thomas C, Moley JF, Origitano T, and Sizemore GW
- Subjects
- Adult, Humans, Male, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-ret, Receptor Protein-Tyrosine Kinases genetics, Brain Neoplasms secondary, Carcinoma, Medullary secondary, Drosophila Proteins, Multiple Endocrine Neoplasia Type 2a pathology, Thyroid Neoplasms pathology
- Abstract
Medullary thyroid carcinoma (MTC) is an uncommon thyroid cancer occurring in less than 10% of patients with thyroid cancer. Brain metastasis from MTC is exceedingly rare. Only six cases of brain metastasis from MTC have been reported in the literature and none had MTC as a part of multiple endocrine neoplasia (MEN) syndrome. We report a 42-year-old Caucasian male with MEN 2A who presented with neurological symptoms 25 years after total thyroidectomy with lymphadenectomy for MTC metastatic to local lymph nodes. A brain magnetic resonance imaging (MRI) showed a 4-cm cystic mass and a 1-cm nodule in the left frontal-parietal lobe in addition to a 0.8-cm cystic mass in the left frontal lobe and multiple tiny cerebellar metastatic lesions. Partial resection of the cerebral metastasis followed by whole brain radiotherapy resulted in resolution of the neurological symptoms. However, the patient had multiple systemic metastasis from the MTC and he died of systemic complications due to metastatic MTC. To our knowledge this is the first report of brain metastases from MTC in a patient with MEN 2A.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.